NSPR - InspireMD, Inc. - AMEX.

Leone70

Nuovo Utente
Registrato
4/5/04
Messaggi
545
Punti reazioni
38
1) Mi ha incuriosito il grafico,,,diciamo che siamo in zona acquisto.
2) Anche gli Insiders si sono incuriositi e stanno acquistando a manetta.
3) Ottimo settore, di nicchia, ma va alla grande (aumento malattie cardiovascolari)
4) Fond lasciamo stare.
5) Monitoriamo ora 2.07$


Adesso 3.05$ ;)
 
Ultima modifica:
1) Mi ha incuriosito il grafico,,,diciamo che siamo in zona acquisto.
2) Anche gli Insiders si sono incuriositi e stanno acquistando a manetta.
3) Ottimo settore, di nicchia, ma va alla grande (aumento malattie cardiovascolari)
4) Fond lasciamo stare.
5) Monitoriamo ora 2.07$



ora quota 2.52$
 
visto che accumulazione pazzesca di volumi?
 

Allegati

  • chart.png
    chart.png
    27,9 KB · Visite: 467
se stornasse area 2.55/2.6...

visto che accumulazione pazzesca di volumi?
:cool



InspiredMD
InspiredMD (NSPR) is a medical device company focusing on the development and commercialization of its proprietary stent platform technology, MGuard. This stock is trading up 2.3% to $2.59 in recent trading.
Today’s Range: $2.44-$2.65

52-Week Range: $1.88-$10.16

Volume: 313,000

Three-Month Average Volume: 99,632
From a technical perspective, NSPR is trending higher here right off its 50-day moving average at $2.42 with heavy upside volume. This stock has been getting heavy upside volume flows for the last few weeks, which is bullish technical action. Shares of NSPR are now quickly moving within range of triggering a major breakout trade. That trade will hit if NSPR manages to take out some near-term overhead resistance levels at $2.85 to $3 with high volume.
Traders should now look for long-biased trades in NSPR as long as it’s trending above its 50-day at $2.42 and then once it sustains a move or close above those breakout levels with volume that hits near or above 99,632 shares. If that breakout triggers soon, then NSPR will set up re-test or possibly take out its next major overhead resistance levels at $3.55 to $4.25. This stock could even tag its 200-day at $4.80 if it breaks out soon and catches some momentum buying.
To see more stocks that are making notable moves higher today, check out the Stocks Under $10 Moving Higher portfolio on Stockpickr.
-- Written by Roberto Pedone in Madison, Wis.
 
Ultima modifica:
1) Mi ha incuriosito il grafico,,,diciamo che siamo in zona acquisto.
2) Anche gli Insiders si sono incuriositi e stanno acquistando a manetta.
3) Ottimo settore, di nicchia, ma va alla grande (aumento malattie cardiovascolari)
4) Fond lasciamo stare.
5) Monitoriamo ora 2.07$


Adesso 3.05$ ;)
 
1) Mi ha incuriosito il grafico,,,diciamo che siamo in zona acquisto.
2) Anche gli Insiders si sono incuriositi e stanno acquistando a manetta.
3) Ottimo settore, di nicchia, ma va alla grande (aumento malattie cardiovascolari)
4) Fond lasciamo stare.
5) Monitoriamo ora 2.07$


Adesso 3.05$ ;)

Ciao belloOK!
Ti se messo a fare lo stock hunter?
 
Cominciamo con una buona notizia:

TEL AVIV, Israel, April 16, 2013 /PRNewswire/ --

InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR) announced the closing of an underwritten public offering of 12.5 million shares of its common stock at a price to the public of $2.00 per share. The Company received net proceeds of approximately $22.6 million, after deducting underwriting discounts and commissions and other offering-related costs. InspireMD granted the underwriters a 30-day option to purchase up to an additional 1.875 million shares to cover over-allotments, if any.

The Company intends to use a portion of the proceeds from the offering to assist in retiring its convertible debentures, to support the worldwide commercialization of the MGuard[TM] Coronary and Carotid Embolic Protection Stents (EPS), to pursue FDA approval in the United States, and for general corporate purposes. Following this offering, the Company will not have any indebtedness for borrowed money outstanding.

OK!
 
Il titolo è quotato da quasi 2 anni al NYSE. E ha quasi sempre veleggiato a quote molto piu' interessanti rispetto a 3$ ca di ora.:)
da verificare il crollo dal 30.10 dell'anno scorso:)

Chiedo un time out per la verifica:)
 
Questo è il motivo:

Results of Operations

Three Months Ended September 30, 2012 Compared to Three Months Ended September 30, 2011

Revenues. For the three months ended September 30, 2012, total revenue decreased approximately $1.5 million, or 74.4%, to approximately $0.5 million from approximately $2.0 million during the same period in 2011. The following is an explanation of the approximately $1.5 million decrease in revenue broken down by its main two components, a decrease in gross revenues of approximately $1.6 million, partially offset by a net increase in deferred revenues of approximately $0.1 million.

For the three months ended September 30, 2012, total gross revenue decreased by approximately $1.6 million, or approximately 78.4%, to approximately $0.4 million from approximately $2.0 million during the same period in 2011. This decrease in total gross revenue was predominately sales volume based, with decreased sales volume accounting for approximately $1.5 million, or approximately 76.5%, and price decreases to our repeat distributors accounting for the remaining approximately $0.1 million, or approximately 1.9%. The $1.5 million decrease was attributable primarily to activities in anticipation of the release of our MASTER trail results at the Transcatheter Cardiovascular Therapeutics (TCT) meeting in Miami Florida, which included evaluating and appointing new distributors in some territories, as well as replacing third party distributors with direct sales channels in key European countries where end user average selling prices and the lack of strong distributors are limiting current sales
***

Il cda ha fatto poi casino con r/s autorizzati e noneffettuati e il mercato ha bastoato il titolo:wall:;)
 
Chiaramente da metà aprile il titolo è stato MANIPOLATO alla grande:)

Penso infatti che si tornerà facilmente a 2$ in pochi giorni:)
 
Direi che il livello a 1,24 non era il fondo...
Spero che l'attuale quotazione a 0,59 sia il pavimento da cui ripartire...
Il 25 c.m. sono attesi i dati...ma il rischio di delisting e' reale.
Incrociamo le dita....
 
Direi che il livello a 1,24 non era il fondo...
Spero che l'attuale quotazione a 0,59 sia il pavimento da cui ripartire...
Il 25 c.m. sono attesi i dati...ma il rischio di delisting e' reale.
Incrociamo le dita....

già fissata la data per il possibile delisting?
 
-44% okkio
 
Indietro